Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 3965

Next Previous
X
Search
Drug Profile

AZD 3965

Alternative Names: AZD-3965

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; University of Newcastle upon Tyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Monocarboxylic acid transporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Burkitt's lymphoma; Solid tumours

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in United Kingdom (PO, Capsule)
  • 09 Jun 2022 Pharmacodynamics data from preclinical studies in Cancer presented at the 27th Congress of the European Haematology Association (EHA-2022)
  • 11 Dec 2021 AstraZeneca presented pharmacodynamics data from preclinical studies at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top